|

AZD6234 Clinical Trials

3 actively recruiting trials across 3 locations

▲ +2 trials since August 2026

Pipeline

Phase 1: 1Phase 3: 2

Top Sponsors

  • AstraZeneca3

Indications

  • Obesity or Overweight2
  • Diabetes2
  • With/Without Diabetes Mellitus, Type 21
  • Weight-Related Comorbidity1
  • Hepatic Impairment1

Dothan, Alabama1 trial

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Research Site

Phase 3

Chandler, Arizona1 trial

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

Research Site

Phase 1

Escondido, California1 trial

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.